ReviewDiscover mental health2026
Broadening the scope of multimodal precision prevention in Alzheimer's disease research.
Review in Discover mental health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWithin the last decade, translational research into Alzheimer's disease and related dementias (ADRD) has embraced the complexity of disease mechanisms and pluralistic approaches to therapeutics. As part of this broader shift, the "multimodal precision prevention paradigm" has emerged as an actionable approach to reduce the public health burden of ADRD.
objectiveTo provide an overview of the definitions, scope, and limitations of the multimodal precision prevention paradigm for ADRD and propose a broader definition of translational research in ADRD research and policy.
methodsThis article performs a critical analysis of leading proposals by different international research initiatives working on multimodal precision medicine for ADRD prevention. MAIN
resultsWithin the multimodal precision prevention paradigm, two overlapping approaches are distinguished on a continuum: on one hand, researchers predominantly from the global North propose a multimodal therapy approach. On the other hand, authors from the global South are proposing a "multimodal diversity" approach stressing the need for a deeper understanding of, and action against, broader contributors to risk of ADRD. It is argued that the complexity of multimodal diversity requires extending the scope of what is typically called "translational research" beyond the "bench-to-bedside" metaphor to include broader policy entry points for prevention (such as action against the social determinants of ADRD).
conclusionsTranslational research into ADRD faces a choice between narrow and broader policy entry points. This article suggests a broader definition of translational research as follows: translational research in Alzheimer's disease and Alzheimer's disease-related dementias should promote a multi-directional interaction between, and multimodal integration of, laboratory-based and diverse population research to achieve a robust, global understanding of brain health and disease that can inspire equitable public health policy and advance precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.